Actively Recruiting
Cefixime Clinical Trial
Led by University of Southern California · Updated on 2026-05-04
400
Participants Needed
1
Research Sites
314 weeks
Total Duration
On this page
Sponsors
U
University of Southern California
Lead Sponsor
A
AIDS Healthcare Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis.
CONDITIONS
Official Title
Cefixime Clinical Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with primary, secondary, or early latent syphilis with RPR titer 1:8 within 3 weeks before enrollment
- 18 years of age or older
- Able to provide informed consent
- If living with HIV, must be on treatment and virologically suppressed (viral load <200 copies/mL) or have a CD4 count 350 cells/mm3 based on recent labs
You will not qualify if you...
- Pregnant or positive pregnancy test on enrollment day
- Signs or symptoms of neurosyphilis
- Persistent positive RPR titer without a 4-fold change for 12 months or more (serofast)
- Recent (within 7 days) or current use of antibiotics effective against syphilis, such as azithromycin, doxycycline, ceftriaxone, or beta-lactam antibiotics
- HIV-positive individuals with treatment interruption longer than 4 weeks since last viral load or CD4 test
- Allergy to cephalosporins or penicillin
- Unwilling or unable to attend follow-up visits
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Southern California
Los Angeles, California, United States, 90032
Actively Recruiting
Research Team
J
Jeffrey D Klausner
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here